Related Experiment Video
Updated: May 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Development and validation of bioanalytical methods to support clinical study of disitamab vedotin
Baiyang Wu1, Qiaoning Li2, Ling Wang2
1Department of Pharmacology, Binzhou Medical University, Yantai, 264003, Shandong, China.
Abstract:
Disitamab vedotin (RC48), a humanized anti-HER2 antibody conjugated with monomethyl auristatin E (MMAE), is the first antibody-drug conjugate in China with an approved biological license application. A bioanalytical method was established for three analytes (total antibody, conjugate antibody and free payload) to help characterize their pharmacokinetic behavior in clinical settings. The bioanalytical methods were validated according to M10 guidance. Electrochemiluminescence assay methods were used for the quantitative measurement of total antibody and conjugated antibody in human serum. A LC-MS/MS method was used to quantify the concentration of MMAE in human serum. The method had high specificity and sensitivity with a quantitative range of 19.531-1250.000 ng/ml (total antibody), 39.063-5000.000 ng/ml (conjugated antibody) and 0.04-10.0 ng/ml (MMAE), respectively.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Measurement of Bioavailability: Pharmacodynamic Methods
In Vitro Drug Release Testing: Overview, Development and Validation
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Automated Microbial Diagnostics

